{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:29:43Z","timestamp":1789831783570,"version":"4.0.1"},"reference-count":41,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"9","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2023,9,6]]},"DOI":"10.1167\/tvst.12.9.5","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:31:07Z","timestamp":1694014267000},"page":"5","source":"Crossref","is-referenced-by-count":14,"title":["Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep)"],"prefix":"10.1167","volume":"12","author":[{"given":"Muneto","family":"Mogi","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha E.","family":"Mendonza","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chastain","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Demirs","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quintus G.","family":"Medley","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien P. N.","family":"Papillon","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongYao","family":"Xu","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Stasi","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000099252","article-title":"Anatomy and immunology of the ocular surface","volume":"92","author":"Knop","year":"2007","journal-title":"Chem Immunol Allergy"},{"issue":"3","key":"bib2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"issue":"5","key":"bib3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","article-title":"Corneal nerves: structure, contents and function","volume":"76","author":"M\u00fcller","year":"2003","journal-title":"Exp Eye Res"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"610342","DOI":"10.3389\/fncel.2020.610342","article-title":"Morphological and functional changes of corneal nerves and their contribution to peripheral and central sensory abnormalities","volume":"14","author":"Guerrero-Moreno","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"bib5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ajo.2011.11.030","article-title":"Impact of ocular surface symptoms on quality of life in a United States Veterans Affairs population","volume":"153","author":"Pouyeh","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"bib6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-020-00263-9","article-title":"Ocular surface pain: a narrative review","volume":"9","author":"Mehra","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"1\u20132","key":"bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/08820538.2015.1114853","article-title":"Understanding neuropathic corneal pain\u2014gaps and current therapeutic approaches","volume":"31","author":"Goyal","year":"2016","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"bib8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40135-017-0152-1","article-title":"Diagnosis and treatment of ocular pain: the ophthalmologist's perspective","volume":"5","author":"Jacobs","year":"2017","journal-title":"Curr Ophthalmol Rep"},{"issue":"10","key":"bib9","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.jcrs.2014.08.001","article-title":"Efficacy and safety of pain relief medications after photorefractive keratectomy: review of prospective randomized trials","volume":"40","author":"Faktorovich","year":"2014","journal-title":"J Cataract Refract Surg"},{"issue":"8","key":"bib10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jcrs.2004.05.019","article-title":"Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients","volume":"30","author":"Solomon","year":"2004","journal-title":"J Cataract Refract Surg"},{"issue":"6","key":"bib11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.survophthal.2012.11.004","article-title":"Management of post-photorefractive keratectomy pain","volume":"58","author":"Woreta","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fnana.2015.00071","article-title":"Transient receptor potential cation channel subfamily V member 1 expressing corneal sensory neurons can be subdivided into at least three subpopulations","volume":"9","author":"Alamri","year":"2015","journal-title":"Front Neuroanat"},{"issue":"6","key":"bib13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00418-012-0924-5","article-title":"Calcium regulation by thermo- and osmosensing transient receptor potential vanilloid channels (TRPVs) in human conjunctival epithelial cells","volume":"137","author":"Mergler","year":"2012","journal-title":"Histochem Cell Biol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"590261","DOI":"10.3389\/fimmu.2020.590261","article-title":"Involvement of neural transient receptor potential channels in peripheral inflammation","volume":"11","author":"Silverman","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"bib15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/pharmaceutics14091859","article-title":"Transient receptor potential channels: important players in ocular pain and dry eye disease","volume":"14","author":"Fakih","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"bib16","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1097\/PR9.0000000000000922","article-title":"Transient receptor potential vanilloid subtype 1 depletion mediates mechanical allodynia through cellular signal alterations in small-fiber neuropathy","volume":"6","author":"Chang","year":"2021","journal-title":"Pain Rep"},{"issue":"1","key":"bib17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40265-020-01429-2","article-title":"TRPV1-targeted drugs in development for human pain conditions","volume":"81","author":"Iftinca","year":"2021","journal-title":"Drugs"},{"issue":"13","key":"bib18","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1523\/JNEUROSCI.4833-06.2007","article-title":"The vanilloid receptor TRPV1 is tonically activated in\u00a0vivo and involved in body temperature regulation","volume":"27","author":"Gavva","year":"2007","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pain.2008.01.024","article-title":"Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans","volume":"136","author":"Gavva","year":"2008","journal-title":"Pain"},{"issue":"6","key":"bib20","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1097\/PR9.0000000000000696","article-title":"NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain","volume":"3","author":"Arsenault","year":"2018","journal-title":"Pain Rep"},{"issue":"4","key":"bib21","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1097\/PR9.0000000000000576","article-title":"TRPV1 antagonist JNJ-39439335 (Mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study","volume":"1","author":"Manitpisitkul","year":"2016","journal-title":"Pain Rep"},{"issue":"14","key":"bib22","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Moreno-Monta\u00f1\u00e9s","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"suppl 1: M11","key":"bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1876386301306010108","article-title":"TRPV1 antagonists as analgesic agents.","volume":"6","author":"Trevisani","year":"2013","journal-title":"Open Pain J"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1358\/dof.2003.028.08.747395","article-title":"Small molecules targeting the vanilloid receptor complex as drugs for inflammatory pain","volume":"28","author":"Planells-Cases","year":"2003","journal-title":"Drugs Future"},{"issue":"1","key":"bib28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157015906775202995","article-title":"Physiology and pharmacology of the vanilloid receptor","volume":"4","author":"Messeguer","year":"2006","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"bib29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/cells3020517","article-title":"TRPV1: a potential drug target for treating various diseases","volume":"3","author":"Brito","year":"2014","journal-title":"Cells"},{"issue":"6","key":"bib30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.exer.2010.03.010","article-title":"TRPV channels mediate temperature-sensing in human corneal endothelial cells","volume":"90","author":"Mergler","year":"2010","journal-title":"Exp Eye Res"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"764396","DOI":"10.3389\/fphar.2021.764396","article-title":"Mechanisms of peripheral and central pain sensitization: focus on ocular pain","volume":"12","author":"Puja","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"bib32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1124\/jpet.107.125674","article-title":"Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade","volume":"323","author":"Gavva","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"21","key":"bib33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S1359-6446(05)03632-9","article-title":"Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development","volume":"10","author":"Whitebread","year":"2005","journal-title":"Drug Discov Today"},{"issue":"11","key":"bib34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/tvst.11.11.15","article-title":"Topical ocular TRPV1 antagonist SAF312 (Libvatrep) demonstrates safety, low systemic exposure, and no anesthetic effect in healthy participants","volume":"11","author":"Stasi","year":"2022","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"bib35","doi-asserted-by":"publisher","first-page":"13267","DOI":"10.1038\/s41598-017-13122-8","article-title":"Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B(4) receptor 2","volume":"7","author":"Iwamoto","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"bib36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0161-6420(95)30998-0","article-title":"Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits","volume":"102","author":"Nassaralla","year":"1995","journal-title":"Ophthalmology"},{"issue":"9","key":"bib37","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2165\/00003495-200767090-00004","article-title":"The role of NSAIDs in the management of postoperative ophthalmic inflammation","volume":"67","author":"Colin","year":"2007","journal-title":"Drugs"},{"issue":"12","key":"bib38","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/archopht.1996.01100140693009","article-title":"Effect of diclofenac, ketorolac, and fluorometholone on arachidonic acid metabolites following excimer laser corneal surgery","volume":"114","author":"Phillips","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"bib39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/jop.1986.2.67","article-title":"Topical ocular drug delivery: recent developments and future challenges","volume":"2","author":"Lee","year":"1986","journal-title":"J Ocul Pharmacol"},{"issue":"4","key":"bib40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/00003088-199018040-00001","article-title":"Ocular drug delivery: pharmacokinetic considerations","volume":"18","author":"Schoenwald","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0939-6411(97)00064-7","article-title":"Ocular pharmacokinetics\/pharmacodynamics","volume":"44","author":"Worakul","year":"1997","journal-title":"Eur J Pharm Biopharm"},{"key":"bib24"},{"key":"bib25","article-title":"Quinazolinone derivatives useful as vanilloid antagonists","author":"Ritchie","year":"June 14, 2011"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2792728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:31:14Z","timestamp":1694014274000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2792728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.12.9.5","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}